{
  "company": {
    "name": "Capstan Therapeutics",
    "website": "https://capstantx.com/",
    "record": "https://startuphistory.org/c/capstantx.com"
  },
  "status": null,
  "history_since": "2021-11-29T05:41:23.000Z",
  "baseline": {
    "snapshot_id": "a8405134ef5ed8ffcae6529456e6bf457a8b0ac88ccbb5e5b0bacaa3ddbdaeb6",
    "observed_at": "2021-11-29T05:41:23.000Z",
    "headline": null,
    "description": "OVH accompagne votre évolution grâce au meilleur des infrastructures web: hébergement, nom de domaine, serveur dédié, CDN, Cloud, Big Data,...",
    "evidence": "https://web.archive.org/web/20211129054123/http://www.capstantx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "blocked",
  "messaging": [
    {
      "quote_observed_at": "2023-09-24T23:52:32.000Z",
      "variants": [
        {
          "headline": "Developing and delivering precise in vivo cell engineering to patients",
          "subhead": "Enabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories. Capstan is combining the power of in vivo cell therapy with the precision ",
          "observed_at": "2022-09-15T04:55:25.000Z",
          "evidence": "https://web.archive.org/web/20220915045525/https://www.capstantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Developing and delivering precise in vivo cell engineering to patients",
          "subhead": "Enabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories. Capstan is combining the power of in vivo cell therapy with the precision ",
          "observed_at": "2023-02-06T16:20:44.000Z",
          "evidence": "https://web.archive.org/web/20230206162044/https://www.capstantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Dedicated to advancing targeted in vivo cell engineering",
          "subhead": "Our core platform technology pertains to proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, and are",
          "observed_at": "2023-09-24T23:52:32.000Z",
          "evidence": "https://web.archive.org/web/20230924235232/https://www.capstantx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Dedicated to advancing targeted in vivo cell engineering",
      "subhead": "Our core platform technology pertains to proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, and are",
      "from": "2022-09-15T04:55:25.000Z",
      "to": "2023-09-24T23:52:32.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20230924235232/https://www.capstantx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2022-09-15T04:55:25.000Z",
          "to": "2023-09-24T23:52:32.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2024-07-13T18:58:21.000Z",
      "variants": [
        {
          "headline": "Multiplying the possibilities for patients",
          "subhead": "Capstan’s mission is to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies.",
          "observed_at": "2024-01-04T09:00:01.000Z",
          "evidence": "https://web.archive.org/web/20240104090001/https://www.capstantx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Multiplying the possibilities™",
          "subhead": "Capstan’s mission is to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies.",
          "observed_at": "2024-07-13T18:58:21.000Z",
          "evidence": "https://web.archive.org/web/20240713185821/https://www.capstantx.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Multiplying the possibilities™",
      "subhead": "Capstan’s mission is to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies.",
      "from": "2024-01-04T09:00:01.000Z",
      "to": "2024-07-13T18:58:21.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20240713185821/https://www.capstantx.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2024-01-04T09:00:01.000Z",
          "to": "2024-07-13T18:58:21.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-5942371108e5717809ed4375f727e9c0d91625527fbfcd7b2806cbdc09aabe26:52ceb0eb6086a4f15b2f050960d362a6c6a33ae1cc010f68d4a059e19c2e12d4:compliance:784f18463d850bcc",
      "before_evidence": "https://web.archive.org/web/20220307061751/http://www.capstantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "compliance",
      "label": "Compliance",
      "summary": "Now states FDA-APPROVED compliance on its homepage.",
      "between": {
        "from": "2022-03-07T06:17:51.000Z",
        "to": "2022-09-15T04:55:25.000Z"
      },
      "evidence": "https://web.archive.org/web/20220915045525/https://www.capstantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-compliance"
    },
    {
      "n": 2,
      "id": "page-b96736361a0ac65a6be80bf74624f44163083753fc5513413696806395c45f1c:7cd81585849a430f1a404f81dac3cd1bc7239353d89f6db3bdf77e1b8645b605:headline:38ba5c5ad1090b29",
      "before_evidence": "https://web.archive.org/web/20230206162044/https://www.capstantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Developing and delivering precise in vivo cell engineering to patients” to “Dedicated to advancing targeted in vivo cell engineering”.",
      "between": {
        "from": "2023-02-06T16:20:44.000Z",
        "to": "2023-09-24T23:52:32.000Z"
      },
      "evidence": "https://web.archive.org/web/20230924235232/https://www.capstantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 3,
      "id": "page-7cd81585849a430f1a404f81dac3cd1bc7239353d89f6db3bdf77e1b8645b605:b48b673ebda2031fadfeddf4897afb291698df74ad68354e75643ead99f744d3:headline:5732f15901ca89cd",
      "before_evidence": "https://web.archive.org/web/20230924235232/https://www.capstantx.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Dedicated to advancing targeted in vivo cell engineering” to “Multiplying the possibilities for patients”.",
      "between": {
        "from": "2023-09-24T23:52:32.000Z",
        "to": "2024-01-04T09:00:01.000Z"
      },
      "evidence": "https://web.archive.org/web/20240104090001/https://www.capstantx.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Capstan Therapeutics” company record, https://startuphistory.org/c/capstantx.com"
}